AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® IN GENERALIZED MYASTHENIA GRAVIS AT AANEM 2024
MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ Patients First and Only Phase 3 Placebo-Controlled gMG Trial for a Biologic That Tapered Corticosteroid Use Amgen (NASDAQ:AMGN) today announced the …